A protease inhibitor, is the third drug in the class for the treatment of hepatitis C
Simeprevir, in combination with pegylated interferon and ribavirin, for treatment of patients with genotype 1 HCV.
Among treatment-naive patients, the SVR12 rate was 80% among those getting all three drugs and 50% among those in the control group, who got placebo along with interferon and ribavirin.
Among relapsers, the SVR12 rates were 79% in the simeprevir group and 36% among placebo patients.